FDA Grants Breakthrough Device Designation to the Prescient Metabiomics LifeKit® Prevent Test for the Early Detection of Colon Polyps and Colon Cancer

September 4, 2019

CARLSBAD, California, September 4th, 2019 -- Prescient Metabiomics, a privately held company and a subsidiary of Prescient Medicine Holdings, Inc., announced that the U.S. Food and Drug Administration (FDA) has granted the company's submission for Breakthrough Device designation to its LifeKit® Prevent Colorectal Neoplasia Test.

Prescient Medicine Holdings Inc. Acquires AutoGenomics Inc.

April 23, 2019

Hummelstown, Pennsylvania, April 23, 2019 - Prescient Medicine Holdings Inc. announced today it has acquired AutoGenomics Inc., a privately-held U.S. molecular diagnostics company, which has developed and commercialized the INFINITI® platform – a 510(k) exempt, automated, microarray-based multiplexing diagnostic system with applications in personalized medicine, pain management, cardiovascular health, mental health, women’s health, oncology, infectious diseases and genetic disorders.

Prescient Medicine’s Dr. Dave Cardamone Lead Reference on Drug Safety Update Published by UK Medicines & Healthcare Products Regulatory Agency

July 17, 2018

In a Drug Safety Update issued by the UK government on July 12, 2018, Dr. Dave Cardamone’s article titled “Eltrombopag and Serum of a Different Hue” is referenced as the lead publication that describes potential negative interference from eltrombopag on bilirubin testing and positive interference on creatinine test values. 

Dr. Keri Donaldson Talks About Using Predictive Insight to Address the Opioid Epidemic on Yahoo Finance

March 7, 2018

Our Founder & CEO, Dr. Keri Donaldson, sat down with Yahoo Finance's Alexis Christoforous to discuss how to tackle the opioid crisis through solutions that help prevent addiction from occurring.

You can view the interview here:

Statement From Prescient CEO & Founder, Keri Donaldson, MD, on Yesterday’s White House Opioid Summit:

March 2, 2018

“I was honored yesterday to be at the White House Opioid Summit on behalf of Prescient Medicine to discuss greater action in the fight against the rising tide of opioid addiction. Data has shown that there is a strong genetic component to opioid addiction, and with the right tools, an individual’s risk of opioid dependency can be predicted. We strongly believe that arming patients and physicians with predictive insight is one of the best solutions to preventing addiction and providing the information needed to make informed decisions before prescribing or taking an opioid.” 

Prescient Medicine Applauds Pennsylvania Governor Tom Wolf’s Declaration of Opioid Crisis as a Statewide Emergency

January 10, 2018

Pennsylvania Governor Tom Wolf took an important step today by designating the opioid crisis as a disaster emergency. The announcement marks Pennsylvania as the eighth state to take this type of action and allows government officials, first responders and others greater ability to implement tactics to address the growing epidemic of opioid addiction.  

Prescient Medicine CEO Keri Donaldson to Participate in US News & World Report’s Panel on Opioid Crisis

November 1, 2017

Sponsorship of “Healthcare of Tomorrow” Leadership Forum Helps Drive Conversation Around Solutions 

HUMMELSTOWN, PA/November 1, 2017 – Prescient Medicine, a Pennsylvania-based predictive health intelligence company, will sponsor the 5th Annual U.S. News & World Report Healthcare of Tomorrow leadership forum, taking place in Washington, DC on November 1-3, 2017. Founder and CEO, Keri Donaldson, MD, will participate as part of the "Taking Action to Address the Opioid Crisis” panel discussion on Friday, November 3rd at 8:45 a.m. E.T. 

Prescient Medicine Continues Growth With Acquisition of Louisville-based PGxL Laboratories

October 5, 2017

Deal Expands Company’s Genetic Testing Capabilities, Managed Care Access

HUMMELSTOWN, PA/October 2, 2017 – Prescient Medicine, a Pennsylvania-based predictive health intelligence company, today announced its acquisition of PGxL Laboratories, a leading reference lab for pharmacogenetics testing. The acquisition will expand Prescient’s laboratory capabilities, and allows the company to grow its relationship with local, regional, and national health insurers, potentially offering patients better access to their suite of pharmacogenomic tools.

Prescient Medicine Hosting Opioid Summit in Philadelphia June 20

May 24, 2017

Prescient Medicine Hosting Opioid Summit in Philadelphia June 20

“SOS: Solving the Opioid Crisis through a Cross-Functional Partnership” will help addiction professionals and others find new ways to address local opioid epidemic

HUMMELSTOWN, Pa., May 24, 2017 -- Prescient Medicine, a leader in Precision Medicine and pharmacogenetics, is pleased to host its first-ever 2017 Opioid Summit, “SOS: SOLVING THE OPIOID CRISIS Through a Cross-Functional Partnership,” June 20 in Philadelphia, Pa. at the Union League Club, 9 a.m. – 3:30 p.m.